In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

according to a new poll from The Associated Press-NORC Center for Public Affairs Research. About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds When it ...

Katherine Wolkoff for The New York Times Supported by By Lisa Miller Lisa Miller interviewed more than two dozen people about the effects weight-loss drugs have had on their romantic relationships ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists currently prescribed for weight ... this new research does not demonstrate that Ozempic and similar drugs can help ...